861P Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
2024 · Annals of Oncology · 4 citations
https://doi.org/10.1016/j.annonc.2024.08.923